ArticleJournal of inflammation research2025
Prognostic Significance of Systemic Immune-Inflammation Index in Patients with de Novo non‑M3 Acute Myeloid Leukemia.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Association between the systemic immune-inflammation index and overall survival in patients with leukemia: a multicenter cohort study.Translational cancer research · 2026Article
- Integrating Blood-Based Immune-Inflammation Biomarkers into Artificial Intelligence-Driven Prognostic Models in Oncology.International journal of molecular sciences · 2026Review
- Analysis of prognostic factors in patients with locally advanced cervical squamous cell carcinoma and development of a nomogram prediction model.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The systemic immune-inflammation index (SII), integrating peripheral neutrophil, platelet, and lymphocyte counts, demonstrates proven prognostic value across malignancies. Its clinical utility in de novo non-M3 acute myeloid leukemia (AML) remains underexplored. Patients and Methods: This retrospective study established the prognostic significance of SII in 262 non-M3 AML patients (diagnosed April 2016-April 2021) and developed a validated survival nomogram. Optimal SII stratification thresholds were determined by X-tile analysis. Clinical characteristics, induction response, overall survival (OS) and event-free survival (EFS) were analyzed. Multivariable Cox regression identified independent prognostic factors for nomogram construction. Model validation included C-index, calibration curves, time-dependent ROC analysis, and decision curve assessment (DCA). Results: X-tile identified 43.3×10 Conclusion: SII is an independent prognostic marker in de novo non-M3 AML. The proposed nomogram, incorporating both SII and established prognostic variables, enables precise and individualized survival prediction. This tool has the potential to inform risk-adapted treatment strategies and guide decision-making in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.